{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:47:37Z","timestamp":1765601257037,"version":"3.48.0"},"reference-count":6,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0466","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T22:10:29Z","timestamp":1765318229000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Effusion Reduction after Early Trastuzumab Deruxtecan Therapy for Unresectable HER2-Low Breast Cancer in an Older Patient: A Case Report"],"prefix":"10.70352","volume":"11","author":[{"given":"Ayaka","family":"Akabane","sequence":"first","affiliation":[{"name":"Department of Surgery I, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Surgery I, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Surgery I, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Surgery I, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Futakuchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyuhiko","family":"Motoi","sequence":"additional","affiliation":[{"name":"Department of Surgery I, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 2020; 38: 1951\u201362.","DOI":"10.1200\/JCO.19.02488"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022; 387: 9\u201320.","DOI":"10.1056\/NEJMoa2203690"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hattori M, Honma N, Nagai S, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast Cancer 2024; 31: 335\u20139.","DOI":"10.1007\/s12282-024-01550-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Yamamoto Y, Yamauchi C, Toyama T, et al. The Japanese Breast Cancer Society clinical practice guidelines for breast cancer, 2022 edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast Cancer 2024; 31: 340\u20136.","DOI":"10.1007\/s12282-024-01566-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nishimura R, Okamoto N, Satou M, et al. HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens. Diagn Cytopathol 2016; 44: 274\u20139.","DOI":"10.1002\/dc.23433"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022; 7: 100554.","DOI":"10.1016\/j.esmoop.2022.100554"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0466\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:42:51Z","timestamp":1765600971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0466\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0466","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0466"}}